(Q42471736)

1 November 2017

Long-term follow-up in 51 patients with mycosis fungoides and Sézary syndrome treated by interferon-alfa (English)

1 reference

1 November 2017

1 reference

O Jumbou

1

1 reference

1 November 2017

J M N'Guyen

2

1 reference

1 November 2017

M H Tessier

3

1 reference

1 November 2017

B Legoux

4

1 reference

1 November 2017

B Dréno

5

1 reference

1 November 2017

language of work or name

English

0 references

publication date

1 March 1999

1 reference

British Journal of Dermatology

1 November 2017

1 reference

1 November 2017

140

1 reference

1 November 2017

3

1 reference

1 November 2017

427-431

1 reference

The role of recombinant interferon alfa-2a in the therapy of cutaneous T-cell lymphomas

1 November 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.1999.02704.X

Phase II trial of intermittent high-dose recombinant interferon alfa-2a in mycosis fungoides and the Sézary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.1999.02704.X

Induction of myelo-monocytic My7 antigen (CD13) expression by interferon-alpha in basal cells of cutaneous T-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.1999.02704.X

Expression of aminopeptidase-n (CD 13) in normal tissues and malignant neoplasms of epithelial and lymphoid origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.1999.02704.X

Intramuscular low dose alpha-2B interferon and etretinate for treatment of mycosis fungoides

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.1999.02704.X

10.1046/J.1365-2133.1999.02704.X

21 January 2018

Identifiers

DOI

1 reference

1 November 2017

1 reference